Table 2 Baseline disease characteristics (intention-to-treat population)

RA duration, mean (SD), years

7.3 (8.6)

6.4 (6.7)

6.9 (7.7)

RF or anti-CCP antibody positive, n (%)

249 (76.9)

267 (81.9)

516 (79.4)

Swollen joint count, mean (SD)

16.1 (9.4)

16.3 (8.7)

16.2 (9.1)

Tender joint count, mean (SD)

24.7 (13.9)

25.7 (12.9)

25.2 (13.4)

 Mean (SD)

25.8 (24.3)

25.3 (28.4)

25.6 (26.4)

 Median (range)

17.9 (0.5–135.0)

16.5 (0.8–203.0)

17.4 (0.5–203.0)

DAS28-CRP, mean (SD)

6.0 (1.0)

6.0 (0.9)

6.0 (0.9)

HAQ-DI, mean (SD)

1.6 (0.6)

1.6 (0.7)

NC

Prior use of one biologic drug, n (%)

7 (2.2)^a

3 (0.9)

10 (1.5)^a

MTX dose, mean (SD), mg/wk

14.2 (4.5)^b

14.4 (4.5)

14.3 (4.5)^b

Corticosteroid use, n (%)

178 (54.9)

192 (58.9)

370 (56.9)

Antimalarial drug use,^c n (%)

2 (0.6)

5 (1.5)

7 (1.1)

Sulfasalazine drug use,^c n (%)

2 (0.6)

2 (0.6)

4 (0.6)